Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

INDS vs NURE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NURE Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 1–2 Matrix Metrics)

NURE Overall Winner 6-Pillar Tally: INDS 0 – 0 NURE (6 Tie) Matrix Metrics: INDS 2 – 1 NURE

As of Nov 16, 2026, Nuveen Short-Term REIT ETF (NURE) is the stronger overall head-to-head candidate over Pacer Industrial Real Estate ETF (INDS) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). INDS carries a Unified Composite Score of 40.7/100 (SELL) at $39.99 (N/M Forward P/E, N/A operating margin), whereas NURE carries 33.6/100 (SELL) at $32.53 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While INDS currently prints a higher short-term Unified Composite Score (40.7/100 SELL vs. NURE 33.6/100 SELL), NURE captures the overall institutional head-to-head verdict (1–2 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Defensive Composite Rating Caution: Although NURE compares more favorably head-to-head, both INDS (40.7/100 SELL) and NURE (33.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INDS vs NURE
INDS NYSE Arca
Pacer Industrial Real Estate ETF
Institutional Equity
$39.99
-0.23% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.42β · 17% Vol
Unified Composite Score
40.7 / 100 SELL
Tech 43.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 58.8 · SMA20: $39.49 · SMA50: $38.60
NURE Cboe BZX Head-to-Head Winner
Nuveen Short-Term REIT ETF
Institutional Equity
$32.53
+0.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.26β · 18% Vol
Unified Composite Score
33.6 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 61
RSI-14: 60.7 · SMA20: $32.01 · SMA50: $30.80

6-Pillar Scorecard Institutional Category Breakdown (INDS 0 – 0 NURE)

Columns: Metric · INDS · NURE
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INDS (2) vs NURE (1)
Institutional Metric INDS NURE Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
57% ($36–$43) 86% ($27–$33) Stronger Trend NURE
Beta / 30D Volatility
Risk Regime
0.42β · 17% Vol 0.26β · 18% Vol Lower Realized Risk INDS
Unified Institutional Score
Composite Signal
40.7 / 100 (SELL) 33.6 / 100 (SELL) Higher Composite INDS
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NURE +0.82 pp
INDS: +5.56% · NURE: +6.38%
3M Horizon NURE +5.29 pp
INDS: -2.73% · NURE: +2.56%
6M Horizon NURE +6.55 pp
INDS: +2.11% · NURE: +8.66%
1Y Horizon NURE +10.22 pp
INDS: +6.51% · NURE: +16.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INDS vs NURE. Trailing 12-month operating profitability (INDS N/A vs NURE N/A) and valuation multiples (INDS N/M vs NURE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

INDS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
NURE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INDS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact INDS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NURE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NURE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INDS Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NURE Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ INDS vs NURE Key Questions & Quantitative Answers

As of Nov 16, 2026, Nuveen Short-Term REIT ETF (NURE) is the stronger overall head-to-head candidate over Pacer Industrial Real Estate ETF (INDS) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). INDS carries a Unified Composite Score of 40.7/100 (SELL) at $39.99 (N/M Forward P/E, N/A operating margin), whereas NURE carries 33.6/100 (SELL) at $32.53 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While INDS currently prints a higher short-term Unified Composite Score (40.7/100 SELL vs. NURE 33.6/100 SELL), NURE captures the overall institutional head-to-head verdict (1–2 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Defensive Composite Rating Caution: Although NURE compares more favorably head-to-head, both INDS (40.7/100 SELL) and NURE (33.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

INDS and NURE split Growth & Scale metrics: INDS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with NURE at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, INDS generates N/A in USD-normalized revenue versus N/A for NURE. In operating R&D and SG&A reinvestment, INDS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NURE.

INDS and NURE trade at balanced relative valuation multiples. INDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NURE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INDS (N/A ROE) versus NURE (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, INDS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.42β · 17% Vol realized risk). By comparison, NURE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.26β · 18% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.